Clinical characteristics, symptoms and outcomes of 1054 adults presenting to hospital with suspected COVID-19: A comparison of patients with and without SARS-CoV-2 infection
- PMID: 32998038
- PMCID: PMC7521430
- DOI: 10.1016/j.jinf.2020.09.033
Clinical characteristics, symptoms and outcomes of 1054 adults presenting to hospital with suspected COVID-19: A comparison of patients with and without SARS-CoV-2 infection
Abstract
Objectives: Most reports describing the characteristics of patients hospitalised with COVID-19 lack a comparator group. We compared clinical characteristics, symptoms, and outcomes of adults presenting to hospital during the pandemic first wave, who tested positive and negative for SARS-CoV-2.
Methods: Detailed patient data was obtained from a large, controlled, non-randomised trial of molecular point-of-care testing versus laboratory RT-PCR for SARS-CoV-2 in adults presenting to a large UK hospital with suspected COVID-19.
Results: 1054 patients were included: 352 (33.4%) tested positive and 702 (66.6%) negative. 13.4% (47/352) COVID-19-positive patients had COPD versus 18.7% (131/702) of COVID-19-negative patients (difference=5.3% [95%CI -9.7% to -0.5%], p = 0.0297). 5.7% (20/352) of COVID-19-positive patients were smokers versus 16.5% (116/702) of negative patients (difference=-10.8% [-14.4% to -7.0%], p = 0.0001). 70.5% (248/352) of COVID-19-positive patients were White-British versus 85.5% (600/702) of negative patients (difference=-15.0% [-20.5% to -9.7%], p<0.0001). 20.9% (39/187) of COVID-19-positive patients were healthcare workers versus 5.2% (15/287) of negative patients (p<0.0001). Anosmia was reported in 33.1% (47/142) versus 8.8% (19/216) of COVID-19-positive and negative patients respectively (p<0.0001). Non-SARS-CoV-2 respiratory viruses or atypical bacteria were detected in 2.5% (5/197) of COVID-19 patients versus 7.9% (24/302) of COVID-19-negative patients (p = 0.0109). Hospitalisation duration and 30-day-mortality were higher in COVID-19 patients and invasive ventilation was more frequent (11.1% vs 2.8%, p<0.0001), and longer (14.5 vs 4.7 days, p = 0.0015).
Conclusions: There were substantial differences between patients with and without COVID-19 in terms of ethnicity, healthcare worker-status, comorbidities, symptoms, and outcomes. These data can inform healthcare planning for the next phase of the pandemic.
Keywords: COPD; COVID-19; Clinical characteristics; Cohort; Healthcare workers; Outcomes; SARS-CoV-2; Smokers; Symptoms.
Copyright © 2020. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of Competing Interest TWC reports non-financial support from QIAGEN in the form of discounted equipment and consumables for this work. He also reports personal fees from BioMerieux and BioFire LLC, non-financial support from BioMerieux and BioFire LLC, personal fees from Synairgen Research Ltd, Roche, Cidara therapeutics, Janssen, Planet Innovation and Randox diagnostics, and grants from NIHR, all outside this work. Other authors report no conflicts of interest.
Comment in
-
Clinical characteristics of 51,815 patients presenting with positive and negative SARS-CoV-2 swab results in primary health care settings: Priority populations for vaccination.J Infect. 2021 Apr;82(4):84-123. doi: 10.1016/j.jinf.2020.11.014. Epub 2020 Nov 14. J Infect. 2021. PMID: 33197474 Free PMC article. No abstract available.
Similar articles
-
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5. Trials. 2021. PMID: 33430924 Free PMC article.
-
Clinical Characteristics and Outcomes of Hospitalized AECOPDs Secondary to SARS-CoV-2 versus Other Respiratory Viruses.Int J Chron Obstruct Pulmon Dis. 2024 Nov 14;19:2421-2430. doi: 10.2147/COPD.S479968. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 39559372 Free PMC article.
-
Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.Cochrane Database Syst Rev. 2021 Feb 12;2(2):CD013587. doi: 10.1002/14651858.CD013587.pub2. Cochrane Database Syst Rev. 2021. PMID: 33624299 Free PMC article.
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Remdesivir for the treatment of COVID-19.Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962. Cochrane Database Syst Rev. 2021. Update in: Cochrane Database Syst Rev. 2023 Jan 25;1:CD014962. doi: 10.1002/14651858.CD014962.pub2. PMID: 34350582 Free PMC article. Updated.
Cited by
-
Association of frailty status with adverse clinical outcomes in patients with COVID-19: protocol for a systematic review and dose-response meta-analysis.BMJ Open. 2021 May 3;11(5):e046980. doi: 10.1136/bmjopen-2020-046980. BMJ Open. 2021. PMID: 33941633 Free PMC article.
-
Clinical Characteristics and Outcomes of COVID-19 Patients in Mazandaran Province, Iran.Tanaffos. 2023 Jan;22(1):102-111. Tanaffos. 2023. PMID: 37920321 Free PMC article.
-
Effect of asthma, COPD, and ACO on COVID-19: A systematic review and meta-analysis.PLoS One. 2022 Nov 1;17(11):e0276774. doi: 10.1371/journal.pone.0276774. eCollection 2022. PLoS One. 2022. PMID: 36318528 Free PMC article.
-
SARS-CoV-2 and post-donation information: a one-year experience of the French haemovigilance network.Blood Transfus. 2022 Sep;20(5):362-373. doi: 10.2450/2022.0266-21. Epub 2022 Jan 21. Blood Transfus. 2022. PMID: 35175185 Free PMC article.
-
A systematic review on cough sound analysis for Covid-19 diagnosis and screening: is my cough sound COVID-19?PeerJ Comput Sci. 2022 Apr 25;8:e958. doi: 10.7717/peerj-cs.958. eCollection 2022. PeerJ Comput Sci. 2022. PMID: 35634112 Free PMC article.
References
-
- World Health Organisation, Coronavirus disease (COVID-19) Situation Report – 209 16 August 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/2... [Last accessed 17 August 2020].
-
- UK Government: https://coronavirus.data.gov.uk/ [Last accessed 17 August 2020].
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous